Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hedge Funds-News
Deerfield Management’s Top Health Stocks ~ Auspex Pharmaceuticals Inc (ASPX), Horizon Pharma PLC (HZNP), AbbVie Inc (ABBV)
Read more at http://www.insidermonkey.com/blog/deerfield-managements-top-health-stocks-auspex-pharmaceuticals-inc-aspx-horizon-pharma-plc-hznp-abbvie-inc-abbv-350499/#ROKhb1QppOrzXKMM.99
Deerfield Management’s second-largest health investment was in Horizon Pharma PLC (NASDAQ:HZNP), in which it owns 12.79 million shares valued at $332.23 million. The specialty biopharmaceutical company has a market cap of $5.02 billion and its shares currently trade at $32.28. Horizon Pharma completed the acquisition of Horizon Therapeutics Inc (NASDAQ:HPTX) on May 7 with a tender offer for 86% of the outstanding shares of the latter. With this acquisition, Horizon Pharma PLC (NASDAQ:HZNP) added two successful medicines for the treatment of urea cycle disorders, RAVICTI and BUPHENYL, to its portfolio. The biopharmaceutical company reported net sales of $113.1 million during the first quarter of 2015 with a net loss of $19.6 million. Broadfin Capital and Healthcor Management LP are two other health-focused investment firms that hold major positions in Horizon Pharma PLC (NASDAQ:HZNP), which has gained an even-more-impressive 152% year-to-date.
Read more at http://www.insidermonkey.com/blog/deerfield-managements-top-health-stocks-auspex-pharmaceuticals-inc-aspx-horizon-pharma-plc-hznp-abbvie-inc-abbv-350499/#ROKhb1QppOrzXKMM.99
http://www.insidermonkey.com/blog/deerfield-managements-top-health-stocks-auspex-pharmaceuticals-inc-aspx-horizon-pharma-plc-hznp-abbvie-inc-abbv-350499/
Investor 100
Transactions @ HZNP
Looking forward to the second half of 2015!
On Friday's call with analysts, Chief Business Officer Robert Carey said Horizon still has $500 million it could spend on acquisitions. "We've got sufficient capacity to execute on our plan right now and hope to continue to be active in the marketplace."
http://news.investors.com/050815-751719-hznp-raises-guidance-after-hptx-buyout.htm?ven=yahoocp&src=aurlled&ven=yahoo
Horizon Pharma plc Completes Hyperion Therapeutics Acquisition
Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc.
Horizon Pharma completes acquisition of Vidara Therapeutics International LTD
Horizon Pharma announces definitive agreement to acquire Vidara Therapeutics International LTD
Horizon Pharma announces agreement to acquire U.S. rights to VIMOVO
Horizon Therapeutics completes merger with Nitec Pharma
http://www.horizonpharma.com/transactions/
Investor 100
Horizon Pharma plc to Participate in Two Conferences in June
http://finance.yahoo.com/news/horizon-pharma-plc-participate-two-144500054.html
Investor 100
Corporate Presentation @ HZNP
Impressive indeed!
http://files.shareholder.com/downloads/AMDA-EFACL/158393936x0x807937/668F9B8B-13FA-41E8-A041-B66CA54BAC83/HZNP_Corporate_Presentation.pdf
Investor 100
Horizon Pharma plc Names John B. Thomas Executive Vice President, Strategy and Investor Relations
http://finance.yahoo.com/news/horizon-pharma-plc-names-john-110000719.html
Investor 100
Upward @ HZNP
Up 5% today!
Tremendous run in 2015 ( 2014 as well )and the train has not yet left the station!
http://www.thestreet.com/story/13115961/1/horizon-pharma-hznp-stock-rises-in-after-hours-trading-following-pricing-of-secondary-offering.html?puc=yahoo&cm_ven=YAHOO
The dip on the offering came and went...bought more too!
Investor 100
Mad Money Cramer @ HZNP
Nice plug on HZNP tonight @ Mad Money!
Investor 100
Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering Announcement
Loading up more on the dip...original cost at $8.50...going much higher!
http://www.thestreet.com/story/13110549/1/horizon-pharma-hznp-stock-falls-in-after-hours-today-following-public-share-offering-announcement.html?puc=yahoo&cm_ven=YAHOO
Investor 100
Moving higher @ HZNP
We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population."
Investor 100
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Solid News to take much higher!
http://finance.yahoo.com/news/horizon-pharma-plc-receives-fda-110000289.html
Investor 100
Horizon Pharma Soars On Q4 Beat, Guidance Raise
Read More At Investor's Business Daily: http://news.investors.com/technology/022715-741245-hznp-stock-hits-high-on-q4-earnings.htm#ixzz3T07z1T6m
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
http://news.investors.com/022715-741245-hznp-stock-hits-high-on-q4-earnings.htm?ven=yahoocp&src=aurlled&ven=yahoo
New Office in Chicago @ HZNP
Horizon Pharma plc Expands U.S. Headquarters With Opening of Chicago Office
Initial Expansion Will Bring More Than 25 Jobs to the City of Chicago
http://finance.yahoo.com/news/horizon-pharma-plc-expands-u-130000183.html
Investor 100
News @ HZNP
Horizon Pharma plc Announces Issuance of VIMOVO(R) Related Patent with Protection to 2031 from United States Patent and Trademark Office
"This patent significantly expands the strength of the VIMOVO patent estate and extends patent protection out to 2031," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "In addition, this patent exhibits our commitment to innovation and ability to further strengthen the intellectual property protection of our portfolio of drugs. This is an important milestone in the commercial lifecycle for VIMOVO."
http://finance.yahoo.com/news/horizon-pharma-plc-announces-issuance-210500771.html
Investor 100
Stockcharts @ HZNP
Full chart...headed to high teens..fell...bought ...upward..
Horizon Pharma plc Provides Business Update
Expands Sales Organization, Accelerates Expansion of Prescriptions-Made-Easy(TM) (PME) Program and Launches PENNSAID(R)2% in United States; Secures Agreement With FDA on ACTIMMUNE(R) Phase 3 Clinical Trial Primary Endpoint
http://finance.yahoo.com/news/horizon-pharma-plc-provides-business-130000001.html
Incestor 100
Horizon Pharma plc to Host Fourth Quarter 2014 Conference Call and Webcast on February 27, 2015
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
Investor 100
Steady Climb @ HZNP
Slow and steady upward...solid start to 2015!
http://openinsider.com/search?q=hznp
Investor 100
Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an ANDA Against PENNSAID(R) 2%
http://finance.yahoo.com/news/horizon-pharma-plc-files-patent-180000945.html
Investor 100